Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA has presented new in vivo data at the ASGCT annual meeting, showcasing the potential of its circVec platform in gene and cell therapy. The data highlights circVec’s ability to enhance protein expression and its distinct tissue expression patterns, suggesting new therapeutic opportunities where conventional gene therapy falls short. The company is advancing its circVec-AAV gene therapy for muscular dystrophies and cardiomyopathies, with promising results indicating enhanced target tissue expression and reduced liver accumulation.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform offers enhanced and durable protein expression, positioning it as a potential gold-standard in nucleic acid and viral therapeutics. Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,111,100
Current Market Cap: NOK63.39M
For an in-depth examination of 0RIS stock, go to TipRanks’ Stock Analysis page.